Skip to main content
. 2022 Mar 22;24(11):1844–1871. doi: 10.1093/europace/euac020

Table 13.

Stratification of thromboembolic risk according to clinical indication for oral anticoagulation

Risk Indication for OAC
AF VTE
High • CHA2DS2-VASc ≥7 • Recent (within 3 months) stroke/TIA • Rheumatic mitral valve disease • Recent (within 3 months) VTE • Severe thrombophilia (e.g. homozygous factor V  Leiden or prothrombin 20 210 mutation, protein C, protein S, or antithrombin deficiency, antiphospholipid syndrome, multiple defects)
Moderate

  • CHA2DS2-VASc 5–6

  • Stroke/TIA >3 months

 • VTE within the past 3–12 months • Non-severe thrombophilia (e.g. heterozygous factor • V Leiden or prothrombin gene mutation) • Recurrent VTE • Active cancer + VTE
Low

  • CHA2DS2-VASc 1–4

  • No history of stroke/TIA

  • • VTE >12 months and no other risk factors

Modified from Ref.179

AF, atrial fibrillation; OAC, oral anticoagulation; TIA, transient ischaemic attack; VTE, venous thromboembolism.